In re Cyclobenzaprine: Secondary Considerations Are Not an Afterthought

In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Eurand, Inc. v. Mylan Pharmaceuticals Inc.), Nos. 2011-1399, -1409, 676 F.3d 1063 (Fed. Cir. Apr. 16, 2012), is the case to cite when a court treats objective indicia of nonobviousness as a tie-breaker rather than as evidence. In an opinion by Judge O’Malley, joined by Judges Newman and Reyna, the Federal Circuit reversed a district court judgment that had held the asserted claims invalid as obvious. The trial court’s methodological error was both subtle and consequential: it found a prima facie case of obviousness first, and only afterward turned to the patentee’s evidence of long-felt need, failure of others, and commercial success to see whether that evidence could overcome a conclusion it had already reached. That sequencing, the Federal Circuit held, is legal error.

At a glance

• Case: In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig., Nos. 2011-1399, -1409 (Fed. Cir. Apr. 16, 2012).
• Panel: Judges Newman, O’Malley, and Reyna; opinion by Judge O’Malley.
• Patents: U.S. Patent Nos. 7,387,793 and 7,544,372, covering an extended-release oral dosage form of cyclobenzaprine (marketed as Amrix) defined by a target pharmacokinetic (PK) profile.
• Posture: Appeal from a district court bench-trial judgment of invalidity in consolidated Hatch-Waxman (ANDA) litigation against generic challengers.
• Holding: The invalidity judgment was reversed and vacated. The district court (1) treated bioequivalence to the immediate-release product as sufficient by itself to render the claims obvious, (2) reached its obviousness conclusion before weighing objective indicia, and (3) improperly shifted the burden of persuasion to the patentee. Properly weighed, the evidence did not support invalidity. The court separately affirmed the district court’s best mode ruling and dismissed the defendants’ appeal from the injunction as premature, so the formal disposition was affirmed in part, reversed in part, vacated in part, and dismissed in part.
• Doctrinal core: Secondary considerations are part of the obviousness analysis itself, not a rebuttal stage; and the burden of persuasion on obviousness stays with the challenger throughout.

The technology and the obviousness theory

Cyclobenzaprine is a muscle relaxant long sold in an immediate-release tablet. The inventors developed an extended-release capsule designed to release the drug over roughly 24 hours, supporting once-daily dosing, and claimed it by reference to a particular set of PK parameters: measures such as peak plasma concentration and total drug exposure over time. The generic defendants’ theory turned on bioequivalence. Bioequivalence means the body is exposed to the same amount of active ingredient at the same rate whether the drug arrives in an immediate-release or an extended-release form. The defendants argued that the claimed extended-release PK profile was bioequivalent to the long-known immediate-release profile, so a skilled formulator would have been able to arrive at the claimed product using known modified-release techniques with a reasonable expectation of success.

The district court accepted that narrative, finding the asserted claims obvious because it believed the claimed extended-release PK profile was bioequivalent to the immediate-release profile. Having reached that conclusion, the court then examined the patentee’s objective evidence and found it insufficient to rebut the result. The patentees (the Federal Circuit referred to the plaintiffs collectively as Cephalon) appealed.

Error one: putting indicia last

The Federal Circuit’s central holding is a statement about the structure of the obviousness inquiry. Under Graham v. John Deere Co., the analysis has four factual predicates: the scope and content of the prior art, the differences between the art and the claims, the level of ordinary skill, and objective indicia of nonobviousness. The fourth factor is not a separate, later phase. The panel grounded that point in its own 1983 decision in Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1538-39, which it quoted at length: evidence rising out of the so-called “secondary considerations” “must always when present be considered en route to a determination of obviousness,” and indeed such evidence “may often be the most probative and cogent evidence in the record.” Stratoflex, the panel explained, holds that a fact finder in district court litigation may not defer examination of the objective considerations until after making an obviousness finding.

The district court inverted that command. By declaring the claims obvious and only then testing whether secondary considerations could rebut the conclusion, it relegated the fourth Graham factor to a rescue operation. The Federal Circuit explained why that is more than a formalist quibble. Objective indicia function as a check against hindsight. They are real-world signals (long-felt but unmet need, the failure of skilled competitors, unexpected results, commercial success tied to the claimed features) that tell a fact-finder whether the invention really was within ordinary reach at the time. A court that forms its obviousness judgment before consulting those signals has already committed the hindsight error the indicia exist to prevent. The fact-finder must weigh all four factors together before deciding.

Error two: shifting the burden of persuasion

The second error concerned burdens. A patent is presumed valid, and a challenger must prove obviousness by clear and convincing evidence. The Federal Circuit drew the now-familiar distinction between the burden of production and the burden of persuasion. The burden of production (the obligation to come forward with evidence) can shift during litigation; once a challenger makes out a prima facie case, a patentee will in practice want to produce rebuttal evidence. But the burden of persuasion never moves: it rests on the challenger, who must persuade the fact-finder of obviousness by clear and convincing evidence on the record as a whole.

The district court, the Federal Circuit found, had effectively required the patentees to disprove obviousness through their secondary-considerations evidence, treating the prima facie case as a presumption the patentee had to overcome. That is the wrong allocation. In litigation (unlike examination at the Patent Office, where the prima facie construct legitimately structures the back-and-forth between examiner and applicant) there is no formal burden-shifting that obligates the patentee to defeat a preliminary conclusion. The challenger must carry the ultimate burden after all evidence, including the patentee’s objective indicia, is on the table.

The reasonable-expectation-of-success problem

Re-weighing the record, the court also found the obviousness theory wanting on its own terms. The claims were defined by a PK profile, yet the record did not establish that a skilled artisan would have known how to achieve that specific profile, or that achieving it would predictably satisfy the claims’ “therapeutically effective plasma concentration over a period of 24 hours” limitation. The court emphasized the absence of a known PK/PD (pharmacodynamic) relationship for cyclobenzaprine: no established link between the blood-concentration profile and the therapeutic effect. Without that link, a formulator could not have had a reasonable expectation that hitting a particular PK target would produce a working drug. The objective evidence reinforced the point: others had not produced such a product despite a long-felt need, which is precisely the kind of real-world signal that undercuts a tidy after-the-fact combination story.

Open questions

• Where is the line between production and persuasion in practice? Cyclobenzaprine is clear that persuasion stays with the challenger, but trial courts still must manage how and when patentees come forward with indicia evidence without inadvertently importing a rebuttal-style presumption.
• How tight must the nexus be? Objective indicia count only when tied to the claimed invention’s merits. The opinion reaffirms the requirement of a nexus but leaves the granular nexus disputes (especially for claims defined by performance parameters) to later cases.
• Does the same rigor apply at the PTAB? The decision arose in district-court litigation. How strictly the “consider indicia first” command applies in inter partes review, where the burden framework and evidentiary posture differ, has been the subject of continuing development.

Implications

• For patent owners: Build the objective-indicia record early and tie each item (long-felt need, failure of others, unexpected results, commercial success) to the claimed features. Then insist that the court weigh that evidence as part of the obviousness determination, not as a rebuttal afterthought.
• For challengers: Do not assume a prima facie case ends the inquiry. The burden of persuasion remains yours through the close of evidence, and a strong indicia record can defeat an otherwise plausible combination theory.
• For trial courts: Sequence matters. Findings should address all four Graham factors together before announcing a conclusion, and the opinion should make clear the challenger carried the clear-and-convincing burden on the whole record.
• For pharmaceutical formulators: Claiming by PK profile is powerful but demands proof that the profile was achievable with a reasonable expectation of success, particularly where no PK/PD relationship was known in the art.

Frequently asked questions

What exactly did the district court do wrong? Two things. It decided the claims were obvious before weighing the patentee’s objective evidence, and it effectively made the patentee disprove obviousness. The Federal Circuit held that indicia must be weighed within the obviousness analysis and that the burden of persuasion stays with the challenger.

Does this case mean secondary considerations always save a patent? No. It means they must be considered as evidence on the merits, alongside the other Graham factors, before any conclusion. Whether they tip the balance still depends on their strength and their nexus to the claimed invention.

How does the burden differ at the Patent Office versus in court? At the Office, a prima facie case structures examination and the applicant must respond. In litigation, the issued patent is presumed valid and the challenger bears the burden of persuasion by clear and convincing evidence throughout; there is no formal shift requiring the patentee to defeat a preliminary finding.

Authorities and sources

• Federal Circuit opinion, full text (FindLaw), In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig., 676 F.3d 1063 (Fed. Cir. 2012): https://caselaw.findlaw.com/court/us-federal-circuit/1608878.html
• Graham v. John Deere Co., 383 U.S. 1 (1966) (Cornell LII): https://www.law.cornell.edu/supremecourt/text/383/1
• Microsoft Corp. v. i4i Ltd. Partnership, 564 U.S. 91 (2011) (Cornell LII), source of the burden-of-production / burden-of-persuasion distinction the panel applied: https://www.law.cornell.edu/supremecourt/text/10-290
• 35 U.S.C. § 282 (presumption of validity) (Cornell LII): https://www.law.cornell.edu/uscode/text/35/282
• Patent Docs analysis (May 2012): https://www.patentdocs.org/2012/05/in-re-cyclobenzaprine-hydrochloride-extended-release-capsule-patent-litigation-fed-cir-2012.html
• Robins Kaplan LLP case summary: https://www.robinskaplan.com/newsroom/insights/in-re-cyclobenzaprine-hydrochloride-extended-release-capsule-patent-litigation